Jean F. Holloway Sells 5,335 Shares of Artivion, Inc. (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT - Get Free Report) SVP Jean F. Holloway sold 5,335 shares of the firm's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $145,698.85. Following the completion of the transaction, the senior vice president now directly owns 149,799 shares of the company's stock, valued at approximately $4,091,010.69. This trade represents a 3.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Artivion Trading Down 0.1 %

Shares of NYSE:AORT traded down $0.02 during trading hours on Friday, hitting $25.34. 568,539 shares of the company's stock traded hands, compared to its average volume of 404,014. Artivion, Inc. has a 1 year low of $18.38 and a 1 year high of $32.33. The business has a fifty day moving average price of $29.51 and a 200-day moving average price of $27.82. The firm has a market capitalization of $1.06 billion, a P/E ratio of -1,267.00 and a beta of 1.75. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33.

Artivion (NYSE:AORT - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of $0.12 by ($0.51). The company had revenue of $97.31 million for the quarter, compared to the consensus estimate of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. Equities analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current year.

Remove Ads

Institutional Investors Weigh In On Artivion

A number of institutional investors and hedge funds have recently bought and sold shares of AORT. Squarepoint Ops LLC lifted its holdings in shares of Artivion by 30.8% in the 4th quarter. Squarepoint Ops LLC now owns 35,707 shares of the company's stock worth $1,021,000 after buying an additional 8,404 shares during the period. Tidal Investments LLC lifted its holdings in shares of Artivion by 14.5% in the 4th quarter. Tidal Investments LLC now owns 179,806 shares of the company's stock worth $5,141,000 after buying an additional 22,804 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Artivion in the 4th quarter worth $64,000. Point72 Asset Management L.P. purchased a new stake in shares of Artivion in the 4th quarter worth $5,573,000. Finally, ProShare Advisors LLC lifted its holdings in shares of Artivion by 44.7% in the 4th quarter. ProShare Advisors LLC now owns 11,924 shares of the company's stock worth $341,000 after buying an additional 3,683 shares during the period. 86.37% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. JMP Securities reiterated a "market outperform" rating and issued a $33.00 price target on shares of Artivion in a research report on Tuesday, December 10th. Stifel Nicolaus dropped their price target on Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research report on Tuesday, February 25th. Oppenheimer lifted their price target on Artivion from $30.00 to $32.00 and gave the stock an "outperform" rating in a research report on Friday, November 8th. Finally, Needham & Company LLC dropped their price target on Artivion from $34.00 to $32.00 and set a "buy" rating for the company in a research report on Tuesday, February 25th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $31.40.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.